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Abstract
Type III Nrg1, a member of the Nrg1 family of signaling proteins, is expressed in sensory neurons, where it can signal in a bi-
directional manner via interactions with the ErbB family of receptor tyrosine kinases (ErbB RTKs) [1]. Type III Nrg1 signaling
as a receptor (Type III Nrg1 back signaling) can acutely activate phosphatidylinositol-3-kinase (PtdIns3K) signaling, as well as
regulate levels of a7* nicotinic acetylcholine receptors, along sensory axons [2]. Transient receptor potential vanilloid 1
(TRPV1) is a cation-permeable ion channel found in primary sensory neurons that is necessary for the detection of thermal
pain and for the development of thermal hypersensitivity to pain under inflammatory conditions [3]. Cell surface expression
of TRPV1 can be enhanced by activation of PtdIns3K [4,5,6], making it a potential target for regulation by Type III Nrg1. We
now show that Type III Nrg1 signaling in sensory neurons affects functional axonal TRPV1 in a PtdIns3K-dependent manner.
Furthermore, mice heterozygous for Type III Nrg1 have specific deficits in their ability to respond to noxious thermal stimuli
and to develop capsaicin-induced thermal hypersensitivity to pain. Cumulatively, these results implicate Type III Nrg1 as a
novel regulator of TRPV1 and a molecular mediator of nociceptive function.
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Introduction
Type III Nrg1, a member of the Nrg1 family of signaling
proteins, is expressed in sensory neurons where it has been shown
to be important for receptor localization as well as nociceptive
sensory neuron survival [2,7]. The Nrg1 gene has also been
identified as a candidate schizophrenia susceptibility gene [8,9,10],
and levels of the Type III isoform were reported to be decreased in
post-mortem tissue of some schizophrenics [11]. Schizophrenia
patients are impaired in their ability to perceive painful stimuli,
particularly under inflammatory conditions [12,13,14,15,16,-
17,18]. We therefore investigated whether reducing levels of Type
III Nrg1 alters response to nociceptive stimuli under normal and
inflammatory conditions.
Transient receptor potential vanilloid 1 (TRPV1) is a cation-
permeable ion channel found in primary sensory neurons that
contributes to the detection of thermal pain and is necessary for
the development of thermal hyperalgesia under inflammatory
conditions [3,19]. Membrane surface expression of TRPV1 can
be enhanced by activation of phosphatidylinositol-3-kinase
(PtdIns3K) [4,5,6] and increased levels of functional surface
TRPV1 along sensory neuron axons contribute to behavioral
sensitization to pain [20].
Type III Nrg1 can signal in a bi-directional manner after
interactions with the ErbB family of receptor tyrosine kinases
(ErbB RTKs). Type III Nrg1 can serve as a ligand to activate
ErbB RTKs and initiate signaling in ErbB-expressing cells [21].
Additionally, Type III Nrg1 can signal as a receptor when
stimulated by interaction with ErbB RTKs or depolarization
[1,22]; Type III Nrg1 signaling as a receptor (Type III Nrg1 back
signaling) can have both transcriptional and non-transcriptional
effects [1,2,22,23]. In particular, Type III Nrg1 back signaling can
acutely activate PtdIns3K along sensory neuron axons [2] making
TRPV1 a potential molecular link between Type III Nrg1,
schizophrenia and alterations in pain sensation.
We now show that mice heterozygous for Type III Nrg1 [7]
have specific deficits in their ability to respond to noxious thermal
stimuli, and in their ability to develop capsaicin-induced thermal
hypersensitivity to pain. These particular behavioral deficits are
reminiscent of mice that lack the receptor TRPV1 [3,19]. A
reduction in levels of Type III Nrg1 is associated with a reduction
in functional TRPV1 along sensory neuron axons. Furthermore,
acute stimulation of Type III Nrg1 back signaling in WT sensory
neuron axons leads to an increase in functional TRPV1 in a
phosphatidylinositol-3-kinase (PtdIns3K)-dependent manner. In
addition to shedding insight into the function of Type III Nrg1 in
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All experiments were conducted in accordance with National
Institutes of Health Guide for the Care and Use of Laboratory Animals
and studies were approved by Institutional Animal Care and Use
Committees at Columbia University (#3132) and Stony Brook
University (#1618 and #1792). Mice heterozygous for an isoform
specific disruption of Type III Nrg1 (Nrg1
tm1Lwr) and their wild-type
littermates were generated and genotyped as previously described
[7]. Animal lines were back-crossed onto a C57/Bl6 background.
WT and Type III Nrg1 heterozygous (Type III Nrg1
+/2)
littermates were generated from heterozygote crosses. TRPV1
2/2
mice were obtained from Jackson Labs. As TRPV1
2/2 mice are
viable and fertile, TRPV1
2/2 crosses were used to generate the
TRPV1
2/2 mice used in experiments. Only male mice were used
for experiments unless specifically stated. Animals were housed 2–4
per cage, maintained on a 12 h light/dark cycle and provided with
food and water ad libitum.
Cell culture
Primary DRG cultures were prepared from P21 WT or Type
III Nrg1
+/2 male mice. Lumbar DRGs were dissected into L-15
media (Sigma) and incubated in a 0.1% collagenase (Type IV,
Worthington) solution for 1 hour at 37uC/5% CO2. Cells were
rinsed once in L-15 before being dispersed in MEM (Gibco)
supplemented with 10% Fetal Bovine Serum (Gemini Bio-
Products), 50 u/ml each of penicillin and streptomycin (Gibco),
2 mM L-glutamine (Gibco) and 50 ng/ml NGF (Harlan Biosci-
ence) using a series of fire-polished pipettes. For immunostaining
and calcium imaging, cells were plated onto 12-mm nitric-
acid washed, poly-D-lysine (1 mg/ml, Chemicon) and laminin
(100 mg/ml, Sigma) coated glass coverslips (Warner Instruments)
at a density of ,4,000 cells/well. Cells were left at 37uC/5% CO2
for 36–48 hours before use. For immunoblots, cells were plated
onto poly-D-lysine and laminin coated cell culture plates (6-well
plate: 20,000 cells/well; 12-well plate: 10,000 cells/well) and left at
37uC/5% CO2 for 48 hours before use.
Reagents
Where indicated, the following reagents were applied to cell
cultures: Capsaicin (Sigma; prepared as a 100 mM stock solution
in 10% ethanol), capsazapine (Tocris Bioscience; prepared as a
10 mM stock in 70% EtOH), 300 ng/ml soluble ErbB4-ECD
(sErbB4-ECD) (Bao et al. 2003), 2.5S nerve growth factor (NGF;
BT-5025 Harlan Bioproducts), 20 nM wortmannin (WM; Cal-
biochem), 50 mM LY294002 (Cell Signaling Technology) and
1 mM PD158780 (Calbiochem).
Behavior
Male WT and Type III Nrg1
+/2 littermates, 5–10 months of
age, were used for behavioral tests. The experimenter was blind to
the genotype of the mice during testing.
Hargreaves Paw Withdrawal Assay
Heat pain threshold of the plantar hindpaw was assessed using
the Hargreaves method [24]. Animals were placed in pairs in
plastic enclosures on an elevated glass plate pre-warmed to 30uC
and allowed to acclimate for 1.5 hours. A focused beam of light
with the percent intensity set to 15 (IITC Life Science) was used to
heat the plantar surface of each hindpaw, and the time for the
animals to withdraw their hindpaws from the light source was
recorded to the hundredth of a second as the reaction latency. For
baseline reaction latency measurements each paw was tested 4
separate times on 2 separate days and the values for each paw
were averaged together by animal. Averages for reaction latency
were compared by genotype.
Cold Plate Test
Noxious cold sensitivity of the plantar surface of the hindpaw
was assessed using a cold plate analgesia meter (IITC Life
Science). To measure pain, mice were placed on the metal surface
pre-set to 0uC, and the latency to generate a nocifensive response
(lifting or flicking the hindpaws or jumping), as well as the total
number of nocifensive responses generated within the five-minute
interval in which the animal remained on the plate, were recorded.
Averages for each variable were compared by genotype.
von Frey Mechanosensitivity Test
Mechanical withdrawal thresholds of the plantar hindpaw were
assessed using the von Frey method. Animals were placed on a
plastic grid in plastic enclosures and allowed to acclimate for
20 minutes. Filaments of increasing durability (IITC Life Science)
were used to apply escalating levels of force to the plantar
hindpaw. Each filament was applied 5 times to the hindpaw and
the number of times the animal withdrew its paw from that
stimulus intensity was recorded and expressed as a percent
response. Average percent response at each stimulus intensity was
compared by genotype.
Modified Hargreaves Paw Withdrawal Assay with
Capsaicin Application
A modified version of the Hargreaves method was used to assess
the development of inflammatory thermal hypersensitivity in the
plantar hindpaw following application of capsaicin. The Har-
greaves Assay was used as described above, with the following
modifications. The glass plate was left at room temperature (25uC)
and the percent intensity of the light source was set to 10 (IITC
Life Science). Baseline measurements were made testing each paw
4 times and the paw withdrawal latencies were averaged by paw.
The following day, animals were lightly anesthetized with 2%
isofluorane, and 20 ml of 0.075% capsaicin cream (Zostrix) was
applied to the right hindpaw and lightly massaged into the skin.
The animals were allowed to recover on the elevated glass plate in
plastic enclosures for 20 minutes before reaction latency was again
assessed for each paw. Absolute reaction latencies, as well as
percent changes from baseline, were compared by genotype.
Histology
For immunofluorescent or immunohistochemical staining of
DRG tissue, adult male mice were deeply anesthetized with a
mixture of ketamine-xylazine (90 mg/kg and 10 mg/kg, respec-
tively) and transcardially perfused with 0.1 M PBS for 2 minutes
followed by 4% paraformaldehyde (PFA) in PBS for 2 minutes.
Following perfusion, L4 and L5 DRG were dissected out
bilaterally, post-fixed in 4% PFA overnight, embedded in paraffin
and cut in 7 mm thick sections on a microtome. Serial sections
from litter matched adult male WT and Type III Nrg1
+/2 mice
were collected on Superfrost plus microscope slides such that each
slide contained representative sections taken approximately every
150 mm throughout the entire DRG. To visualize DRG cell
profiles, paraffin-embedded tissue was subjected to antigen
retrieval, blocked in 10% normal donkey serum (NDS) in PBS
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temperature, and left in primary antibody diluted in PBS-T
overnight at 4uC. Primary antibodies used for cell counting include
those against TrkA (rabbit, 1:2000, gift of L.F. Reichardt),
peripherin (rabbit, 1:1000, ab1530 Millipore and mouse, 1:1000,
ab4573 abcam), and TRPV1 (guinea pig, 1:1000, GP14100
Neuromics), as well as the marker lectin IB4-FITC (1:200 in PBS
containing Ca
2+, L9381 Sigma). Type III Nrg1 was detected using
a Type III-specific antibody generated in our lab (host=chicken)
that recognizes an extracellular epitope of the protein (peptide
sequence: ARTPEVRTPKSGTQPQTTET, corresponding to
residues 195–214 of the Type III Nrg1 protein, KHL conjugated,
Pocono Rabbit Farm & Laboratory Inc). Specific staining of motor
neurons in the ventral horn of the spinal cord was used as a
positive control (data not shown). This staining disappeared when
the antibody was pre-incubated with the peptide against which it
was generated, confirming the specificity of the staining in adult
tissue (data not shown). Serum samples taken from the animal
before it was immunized were used as a negative control and did
not stain the spinal cord, dorsal root ganglia or hindpaw skin (data
not shown). The following day secondary antibodies conjugated to
Biotin (1:500, Jackson ImmunoResearch), Alexa488 (1:500,
Molecular Probes), Alexa594 (1:500, Molecular Probes), Alexa546
(1:500, Molecular Probes) or AMCA (1:50, Jackson ImmunoR-
esearch) (diluted in 10% NDS in PBS-T) were applied for 1 hour
at room temperature. For immunofluorescence, sections were
subsequently coverslipped using Vectashield (Vector Laboratories
Inc, generally containing DAPI) and sealed with nail polish. For
immunohistochemistry, sections were incubated with Avidin-
Biotin Complex (ABC, Vector Laboratories Inc) and developed
using a Diaminobenzidine (DAB) reaction (Vector Laboratories
Inc), before being dehydrated and cleared with ethanol and xylene
washes and mounted using Permount (Fisher Scientific). Co-
localization of Type III Nrg1 with various sensory markers was
assessed by acquiring confocal images of DRG sections using the
Olympus Spinning Disk Confocal microscope (DSU; Olympus)
equipped with a 406oil Plan ApoN objective (1.42 NA), electron-
multiplying charge-coupled device camera (Hamamatsu), and
Slidebook software (Version 5; Olympus).
To count DRG neuronal profiles immunoreactive for a
particular sensory marker, epifluorescent images were acquired
using an Axio Imager microscope (Carl Zeiss, Inc.) equipped with
a2 0 6 Plan-Apochromat objective (0.8 NA), a charge-coupled
device camera (Hamamatsu) and Metamorph software (MDS
Analytical Technologies). A constant exposure time was used for
each sensory marker. Images were analyzed using Metamorph by
creating constant intensity thresholds above which cells were
counted as positively stained. Two independent observers tallied
the number of neuronal profiles positively stained for both the
specific and pan-sensory marker in each tissue section. The results
from both observers were averaged and used to generate
percentages of sensory neurons staining positively for individual
sensory markers. For each marker, counts from at least five tissue
sections per animal were averaged. 3 animals per genotype were
analyzed and genotype averages were compared.
For hindpaw staining, deeply anesthetized male mice were
transcardially perfused with PBS for 4 minutes, plantar skin from
the hindpaw was dissected out and post-fixed in 4% PFA for
18 hours before being cryoprotected in 30% sucrose. Tissue was
embedded in OCT mounting media and stored at 280uC until
sectioning. 20 mm sections were sectioned serially on a cryostat
and stored at 220uC until needed. For TRPV1 hindpaw staining,
mice were given a plantar injection of 1 mg of NGF (in 10 ml
saline) 48 hours prior to transcardial perfusion. Further tissue
preparation was as described above, except for the use of 40 mm
cryostat sections. For immunofluorescent staining, sections were
rehydrated in PBS-T and blocked in 10% NDS in PBS-T for
1.5 hours at room temperature before primary antibodies were
applied overnight at 4uC. Primary antibodies used to stain the
hindpaw include those against CGRP (rabbit, 1:1000, T-4032
Bachem), TRPV1 (guinea pig, 1:1000, GP14100 Neuromics) and
Type III Nrg1 (chicken, 1:2000). The following day, secondary
antibodies conjugated to Alexa488 or Alexa546 (1:500, Molecular
Probes) (diluted in 10% NDS in PBS-T) were applied and sections
were coverslipped with Vectashield (containing DAPI) and sealed
with nail polish.
For immunofluorescent staining of primary DRG cultures, cells
grown for 36–48 hours were rinsed twice in PBS, fixed in 4% PFA,
permeabilized in PBS-T for 10 minutes and blocked in 10% NDS
in PBS for 1 hour at room temperature before incubation with
primary antibody. To assess activation of PtdIns3K along WT and
Type III Nrg1
+/2 axons, cultures were serum-starved for 4 hours,
and then treated with either sErbB4-ECD (300 ng/ml) or NGF
(100 ng/ml) for 15 minutes at 37uC before being stained with
antibodies against pAKT (Ser473, rabbit, 1:200, 4060 Cell
Signaling Technology), Type III Nrg1 (chicken, 1:2:000) and
pan-axonal proteins (mouse, 1:500, SMI-312R Covance) over-
night at 4uC followed by secondary detection with Alexa488-,
Alexa594- or AMCA-conjugated secondary antibodies (diluted in
10% NDS in PBS). Fields of view containing axons selected based
on their expression of Type III Nrg1 and pan-axonal protein were
imaged using epifluorescence, and photographed with a constant
exposure time using an Axio Imager microscope (Carl Zeiss, Inc.)
equipped with a 636 oil Plan-Apochromat objective (1.4 NA), a
charge-coupled device camera (Hamamatsu), and Metamorph
software (MDS Analytical Technologies). At least 5 fields of view
were acquired from each of the three animals per genotype.
Briefly, axons were outlined in Metamorph using the pan-axonal
marker as a guide, the outlined regions were transferred to the
pAKT image, and the average fluorescence intensity (AFI) of the
pAKT staining along these regions was recorded. Intensity of
pAKT staining was averaged by animal within a given treatment
and average pAKT intensity was compared by genotype and
treatment.
To quantify levels of Type III Nrg1 along P21 WT and Type III
Nrg1
+/2 axons, cultures were treated with antibodies that
recognized either an extra-cellular epitope of Type III Nrg1
(chicken, 1:2000, 2 hours at 37uC) or the C-terminal intracellular
domain (Nrg1-ICD, rabbit, 1:200, sc348 Santa Cruz, overnight at
4uC). Cultures were also stained for peripherin (rabbit or mouse,
1:1000), before secondary detection with Alexa488- or Alexa594-
conjugated secondary antibodies (diluted in 10% NDS in PBS).
Fields of view containing axons (identified based on expression of
peripherin) were imaged using epifluorescence using a 636 oil
Plan-Apochromat objective (1.4 NA) and photographed with a
constant exposure time. At least 5 images were acquired from each
of the three animals per genotype. Images were processed with
MetaMorph software. Axons were outlined using peripherin
staining as a guide, and the number of Type III Nrg1+ and
Nrg1-ICD+ punctae along these peripherin+ axons with intensity
greater than a defined threshold value were quantified and
expressed as the number of punctae per 100 mm of axon length.
These values were averaged within a given image and compared
by genotype.
Calcium Imaging
At 3 days in vitro, primary DRG cultures were loaded with
5 mM Fluo-4 Ca
2+ binding dye (Invitrogen) in 16 HEPES
Type III Nrg1, TRPV1 and Pain Sensation
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25108Buffered Saline (HBS) with 2 mM Pluronic-F127 (Invitrogen) for
15 minutes at 37uC/5% CO2. Cells were rinsed 2 times with HBS
and left to rest at 37uC/5% CO2 for 30 minutes before use.
During imaging, cells were perfused with HBS containing 2 mM
tetrodotoxin (TTX, Tocris), 10 mM bicuculline (Tocris), 50 mMD -
(2)-2amino-5-phosphono-valeric acid (D-APV, Tocris) and
20 mM 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX, Tocris) at
a rate of 0.5 ml/minute. Images were captured every 3 seconds
using a spinning disc confocal microscope (DSU; Olympus)
equipped with a 406 oil Plan ApoN objective (1.4 NA),
electron-multiplying charge-coupled device camera (Hamamatsu),
and Slidebook software (Version 5; Olympus). After acquiring
images for 1 min, 1 mM of capsaicin was focally applied by
pressure ejection (Picospritzer II, General Valve Corporation) for
20 seconds. Depending on the experiment, capsaicin was applied
between 1 and 4 additional times. At the end of each experiment,
the cultures were depolarized by application of 56 mM KCl for
20 seconds. Regions (2.5 by 2.5 mm) were drawn along axons that
responded to both capsaicin and KCl and the percent change in
fluorescence intensity from baseline ([(F2F0)/F0]*100) was
calculated within these regions using MetaMorph software. All
regions were averaged by axon; all axons were averaged by animal
and animal averages were compared by genotype and treatment.
For analysis of somal responses, circular regions were drawn just
inside the boundaries of the cell body and [(F2F0)/F0]*100 was
calculated within these regions as described above.
Immunoblotting
For TRPV1, DRG. P21 WT and Type III Nrg1
+/2 DRG
cultures were grown in a 6-well plate, rinsed 2 times on ice with
PBS, lysed into a modified RIPA buffer (95 mM NaCl, 25 mM
Tris pH 7.4, 10 mM EDTA, 1 mM EGTA, 10 mM ammonium
molybdate, 1 mM sodium orthovanadate, 1% SDS and protease
inhibitors) and homogenized using a pipette tip. Lysate was left on
ice for 10 minutes followed by centrifugation at 10,000 rpm for
10 minutes at 4uC. Lysate was mixed with Laemmli buffer, heated
at 37uC, separated on a 7.5% SDS-PAGE gel and transferred to a
nitrocellulose membrane (Whatman). The membrane was then
blocked for 1 hour in 5% milk (Carnation)/Tris Buffered Saline
(TBS) and antibodies directed against TRPV1 (rabbit, 1:1000,
RA14113 Neuromics) and GAPDH (mouse, 1:5000, CB1001
Calbiochem) were applied in 5% milk/Tris Buffered Saline with
0.1% Tween-20 (TBS-T) overnight at 4uC. After three 10-minute
rinses in TBS-T at room temperature, secondary antibodies
conjugated to Alexa680 or Alexa800 (Molecular Probes) or
IRDye-700 or 800 (Rockland) were applied at a concentration
of 1:5000 diluted in 5% milk/TBS-T for 1 hour at room
temperature. Membranes were scanned with an Odyssey
Infrared Imaging System (Li-Cor Biosciences) and band
intensities were analyzed using Odyssey Image Analysis software.
The intensity of the TRPV1 band was normalized to that of
GAPDH to control for variable protein loading. TRPV1-GAPDH
ratios were compared by genotype.
For pAKT and pERK, DRG. P21 WT and Type III Nrg1
+/2
cultures grown in a 12-well culture plate for 36–48 hours were
serum starved for 4 hours before being treated with sErbB4-ECD
(300 ng/ml for 15 minutes) or NGF (100 ng/ml for 5 minutes) at
37uC, rinsed 2 times on ice with TBS and homogenized with a
pipette tip in lysis buffer (1% Ipegal, 30 mM HEPES, 100 mM
NaCl, 25 mM NaF, 10 mM EDTA, 4 mM EGTA, 15 mM sodium
pyrophosphate, 10% glycerol, protease and phosphatase inhibitors,
1 mMPMSF and 5 mMsodiumorthovanadate).The lysate wasleft
on ice for 10 minutes followed by centrifugation at 10,000 rpm for
10 minutes at 4uC. Lysate was mixed with Laemmli buffer, heated
to 90uC for 10 minutes, separated on a 10% SDS-PAGE gel and
transferred to a nitrocellulose membrane. The membrane was then
blocked for 1 hour in 5% milk/TBS and antibodies directed against
pAKT (Ser473, rabbit, 1:1000, 9271 Cell Signaling Technology),
pERK (Thr202/Tyr204, mouse, 9106 Cell Signaling Technology)
and GAPDH were applied in 5% milk/TBS-T overnight for 2
nights at 4uC. Secondary antibodies conjugated to Alexa680 or
IRDye-700 were applied at a concentration of 1:5000 in 5% milk/
TBS-T for 1 hour at roomtemperature and bands were detected by
scanning with the Odyssey Infrared Imaging System. Subsequently,
membranes were re-blocked in 5% milk/TBS-T and incubated in
antibodies directed against AKT (rabbit, 1:1000, 9272 Cell
Signaling Technology) and ERK (rabbit, 1:1000, 9102 Cell
Signaling Technology) diluted in 5% milk/TBS-T overnight at
4uC followed by detection with secondary antibodies conjugated to
Alexa800 or IRDye-800 for one hour at room temperature.
Membranes were rescanned using the Odyssey system and band
intensities were analyzed using Odyssey Image Analysis software.
Ratios of pAKT-AKT and pERK-ERK were determined for each
sample and compared by treatment and/or genotype.
For TRPV1, TrkA and Ret, Hindpaw. P21 WT and Type
III Nrg1
+/2 hindpaw galabrous skin samples were lysed into a
modified RIPA buffer (95 mM NaCl, 25 mM Tris pH 7.4,
10 mM EDTA, 1 mM EGTA, 10 mM ammonium molybdate,
1 mM sodium orthovanadate, 1% SDS and protease inhibitors)
and homogenized using a dounce homogenizer. Lysate was left on
ice for 10 minutes followed by centrifugation at 10,000 rpm for
10 minutes at 4uC. Lysate was mixed with Laemmli buffer, heated
at 95uC, separated on a 7.5% SDS-PAGE gel and transferred to a
nitrocellulose membrane (Whatman). The membrane was then
blocked for 1 hour in 5% milk (Carnation)/Tris Buffered Saline
(TBS) and antibodies directed against TRPV1 (rabbit, 1:500,
RA14113 Neuromics) and GAPDH (mouse, 1:5000, CB1001
Calbiochem) or TrkA (rabbit, 1:500, gift of L.F. Reichardt), Ret
(goat, 1:500, GT15002) and GAPDH (mouse, 1:5000, CB1001
Calbiochem) were applied in 5% milk/Tris Buffered Saline with
0.1% Tween-20 (TBS-T) overnight at 4uC. After three 10-minute
rinses in TBS-T at room temperature, secondary antibodies
conjugated to Alexa680 or Alexa800 (Molecular Probes) or
IRDye-700 or 800 (Rockland) were applied at a concentration
of 1:5000 diluted in 5% milk/TBS-T for 1 hour at room
temperature. Membranes were scanned with an Odyssey
Infrared Imaging System (Li-Cor Biosciences) and band
intensities were analyzed using Odyssey Image Analysis software.
The intensity of the TRPV1, TrkA and Ret bands were
normalized to that of GAPDH to control for variable protein
loading. TRPV1, TrkA or Ret-GAPDH ratios were compared by
genotype.
RT-PCR Analysis of Type III Nrg1 Splice Variants
Relative levels of Type III Nrg1 transcripts containing the TMc
exon versus those containing the b3 exon were measured by semi-
quantitative RT-PCR. Total RNA from thoracic, lumbar and
sacral level DRG from P21 male mice was purified using Trizol
and 2 mg was converted to cDNA using Superscript III
(Invitrogen). 0.5 mg of each cDNA was amplified using either a
CRD 59 and TMc 39 primer pair, a CRD 59 and b33 9 primer
pair, or all three primers together (primer concentrations in each
instance were 200 ng). The resulting products were resolved on an
agarose gel and relative ethidium fluorescence was quantified. The
predicted product sizes for the CRD – TMc product was 359 bp
(assuming the b1 splice form was amplified) and 309 bp for the
CRD-b3 Primer sequences used were: CRD59CAGGAACT-
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b33 9: ACAAGAAAGCAGCACCGACT.
Statistical Significance
Normally distributed data was evaluated using a Student’s t-test
or an ANOVA with a Holm-Sidak or Fischer’s PLSD post-hoc test
for multiple comparisons. Non-normally distributed data was
compared using a Mann-Whitney Rank Sum test or an ANOVA
on Ranks with a Dunn’s post-hoc test for multiple comparisons.
Statistical significance was set at p,0.05.
Results
Type III Nrg1 is found in adult nociceptive sensory
neuron soma and peripheral nerve terminals
In order to determine the pattern of Type III Nrg1 expression in
nociceptive peripheral sensory neurons of the adult mouse, we
used double immunofluorescent labeling of transverse sections
through mouse lumbar DRG (Figure 1A) and plantar hindpaw
skin (Figure 1B). In L4/L5 DRG Type III Nrg1 protein is
expressed in both major classes of nociceptive sensory neurons, the
Figure 1. Type III Nrg1 expression in adult nociceptive sensory neuron soma and peripheral nerve terminals in vivo. (A) Type III Nrg1
(b,e,h) is found in nociceptive TrkA+ (a–c) and IB4+ (d–f), as well as TRPV1+ (g–i) sensory neuron soma in lumbar dorsal root ganglia. (B) Type III Nrg1
(b9,e9) is found in nociceptive peripheral nerve terminals innervating the plantar hindpaw skin as marked with an antibody against CGRP (a9) as well
as TRPV1 (d9). White arrows indicate examples of soma or nerve terminals that are expressing both Type III Nrg1 and the particular sensory marker. All
scale bars equal 10 mm.
doi:10.1371/journal.pone.0025108.g001
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and the non-peptidergic nociceptive sensory neurons (IB4;
Figure 1A(d–f)). Type III Nrg1 is also found in the population of
nociceptive sensory neurons that expresses the thermoreceptor,
TRPV1 (Figure 1A(g–i)). Additionally, we found punctate Type III
Nrg1 expression along nociceptive peripheral nerve terminals
innervating the plantar skin of the hindpaw as evidenced by Type
III Nrg1 co-staining with both the peptidergic marker, CGRP
(Figure 1B(a9–c9), white arrow) as well as TRPV1 (Figure 1B(d9–
e9), white arrows).
Heat pain and thermal hypersensitivity to pain are
reduced in the Type III Nrg1
+/2 mouse
In order to examine the effect of reducing levels of Type III
Nrg1 on pain sensation we tested WT and Type III Nrg1
+/2 adult
male mice in a variety of behavioral assays that probe the ability of
the animals to respond to different modalities, as well as intensities,
of sensory stimuli. We assessed response to noxious heat using the
Hargreaves Paw Withdrawal Assay [24]. We set the intensity of
the radiant heat source (used to heat the animals’ hindpaws over a
thermal gradient) to a level where WT animals withdraw their
paws from the stimulus at 8.0160.21 s and found that under those
parameters the Type III Nrg1
+/2 animals respond significantly
more slowly (9.4560.39 s; p,0.01) (Figure 2A). These latencies
corresponded to the time it took to heat a thermal probe to 40u
and 41uC, respectively. Interesting, these temperatures are in the
range of the proposed gating temperature for TRPV1 [19]. Using
additional behavioral assays, we demonstrated that this deficit in
Type III Nrg1
+/2 animals was specific to noxious heat. When we
assessed response to noxious cold by placing the animals on a
metal plate pre-cooled to 0uC, we found that the Type III Nrg1
+/2
animals actually generated a nocifensive response significantly
faster than their WT littermates (latency to respond: WT,
183637.0 s; Type III Nrg1
+/2, 59.4626.1 s; p,0.01) and
generated more nocifensive responses (WT, 261; Type III
Nrg1
+/2,9 62; p,0.01) in the five minute time frame in which
they were kept on the plate (Figure 2B). We did not observe any
significant differences between genotypes in percent response to
noxious mechanical stimulation with filaments of varying inten-
sities in the von Frey Assay (Figure 2C), further emphasizing the
thermal specificity of the behavioral deficit in the Type III Nrg1
+/2
mice. In aggregate, our studies demonstrate that Type III Nrg1
+/2
animals have selective deficits in noxious heat sensation.
We also wanted to examine the effect of reducing levels of Type
III Nrg1 on the development of inflammatory pain. To do this, we
evaluated response latency in a modified version of the Hargreaves
Paw Withdrawal Assay before and after the induction of
inflammation in the hindpaw. We wished to increase the baseline
Figure 2. Type III Nrg1
+/2 animals have specific behavioral deficits in responding to noxious thermal stimuli. (A) Response in radiant
paw heating assay. Latency to respond to radiant heat (set at 15% of maximum intensity) applied to the hindpaw was evaluated for WT and Type III
Nrg1
+/2 siblings. Response times from both paws were averaged by animal and compared by genotype. Type III Nrg1
+/2 mice showed a significantly
increased latency to respond relative to their WT littermates (WT, n=16 animals; Type III Nrg1
+/2, n=14 animals; **p,0.01). (B) Response to noxious
cold assessed with the cold plate test. Latency to respond to a 0uC stimulus was measured for WT and Type III Nrg1
+/2 mice and compared by
genotype. Type III Nrg1
+/2 mice respond significantly faster than their WT littermates (WT, n=16 animals; Type III Nrg1
+/2, n=14 animals; **p,0.01).
The total number of nocifensive responses that each animal made in the 5 minute period they remained on the 0uC plate was measured and
compared by genotype. Type III Nrg1
+/2 mice made significantly more nocifensive responses than their WT littermates (**p,0.01). (C) Response in
the von Frey assay of mechanosensation. Percent response for the various forces was evaluated for WT and Type III Nrg1
+/2 mice. Data were
compared by genotype for each test force. There were no significant differences between genotypes (WT, n=15 animals; Type III Nrg1
+/2,n=1 4
animals). (D) Response in a modified version of the radiant paw heating assay pre- and post-capsaicin application. Latency to respond to radiant heat
(set at 10% of maximum intensity) applied to the hindpaw was evaluated for WT and Type III Nrg1
+/2 littermates before and after application of 15 ml
of 0.075% capsaicin cream to the right hindpaw. Response latencies following capsaicin application were significantly less depressed in Type III
Nrg1
+/2 animals relative to WTs (WT, n=16 animals; Type III Nrg1
+/2, n=13 animals **p,0.01). Similarly, the percent change (%D) in response latency
for Type III Nrg1
+/2 animals was significantly blunted relative to WTs (*p,0.05). All genotype comparisons were made using a Student’s t-test. All
graphs show the mean6SEM.
doi:10.1371/journal.pone.0025108.g002
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larger window in which to evaluate the extent of hypersensitivity to
pain developed as a result of an inflammation-inducing manipu-
lation to one of the hindpaws. Therefore, we decreased the
intensity of the radiant heat source (from 15% to 10% of
maximum intensity) so that it took a longer time to elicit a
withdrawal response. The new baseline response latencies for the
WT and Type III Nrg
+/2 animals were longer than what they had
been (WT, 21.2261.05 s; Type III Nrg1
+/2, 21.2061.35 s), and
they did not differ significantly from one another (Figure 2D). At
the reduced radiant heat source intensity used in these
experiments, the response latencies of the animals corresponded
to approximately 30uC. In the absence of inflammation, this
temperature is generally not perceived as noxious. Therefore, at
baseline in this experimental paradigm, it is possible that the
animals were withdrawing their paws when they first perceived a
warm stimulus, rather than a painful one. The different intensity of
the thermal stimulus used in these experiments may also explain
why we did not see any difference in response times at baseline
between genotypes. Inflammation was induced by local capsaicin
application to the right hindpaw, and 20 minutes later WT
animals exhibited a robust reduction in response latency indicative
of the development of thermal hypersensitivity to pain (WT post-
capsaicin, 6.2161.06 s; p,0.001 v. WT pre-capsaicin). Type III
Nrg1
+/2 animals also exhibited a reduction in response latency
following capsaicin application (Type III Nrg1
+/2 post-capsaicin,
13.8562.31 s; p,0.01 v. Type III Nrg1
+/2 pre-capsaicin),
although the response latency for Type III Nrg1
+/2 animals
post-capsaicin was significantly greater than WTs (p,0.01;
Figure 2D). Thus, following capsaicin application, the thermal
response latency of WTs decreased by 67% whereas the response
latency of the heterozygous littermates decreased by only 33%
(p,0.05; Figure 2D).
Sensory neuron survival is not affected in Type III Nrg1
+/2
lumbar DRG
Type III Nrg1 is required for TrkA
+ sensory neuron survival
during late embryonic development [7]. Therefore, we undertook
quantitative immunohistochemical analysis of L4/L5 DRG from
adult WT and Type III Nrg1
+/2 mice to assess the effect of
reducing levels of Type III Nrg1 on sensory neuron survival.
Sections were double-labeled with markers for sensory neuron
subgroups (TrkA, IB4, NF200 and peripherin) as well as with a
pan-sensory neuron marker (a cocktail of NF200 and peripherin),
and the percentage of sensory neurons expressing each of the
different markers was calculated. We found that reducing levels of
Type III Nrg1 did not affect the percentages of any of these
sensory neuron populations (TrkA: WT 30.461.9, Type III
Nrg1
+/2 25.363.4; IB4: WT 32.161.9, Type III Nrg1
+/2
29.560.4; NF-200: WT 35.461.9, Type III Nrg1
+/2 33.262.6;
Peripherin: WT 65.061.6, Type III Nrg1
+/2 66.462.9). Finally,
the number of pan-sensory
+ profiles per section from at least five
sections evenly spaced throughout the DRG was averaged for each
animal and animal averages were compared by genotype. There
was no significant difference between the genotypes (Figure 3A;
WT, 141619 profiles/section; Type III Nrg1
+/2, 11469;
Figure 3. Adult WT and Type III Nrg1
+/2 animals have equivalent numbers of sensory neurons and sensory cutaneous projections.
(A) Representative sections through L4/L5 DRG from adult WT and Type III Nrg1
+/2 mice were stained with a pan-sensory marker. Total cells staining
positive for this marker tallied from at least 5 sections evenly spaced throughout the DRG were counted and averaged for each animal. Genotype
averages were compared with a Student’s t-test (n=3 animals per genotype). There was no statistically significant difference between genotypes. (B)
Galabrous hindpaw skin samples from WT and Type III Nrg1
+/2 mice were assessed for total TrkA, Ret and TRPV1 protein using immunoblot. (C) The
intensity of the TrkA, Ret and TRPV1 bands were quantified and normalized to GAPDH to control for equal protein loading. The values were expressed
as a fold change from the average WT value and genotype averages were compared with a Student’s t-test (for TrkA and Ret: WT n=13 paws from 10
animals, Type III Nrg1
+/2 n=13 paws from 9 animals; for TRPV1: WT n=9 paws from 5 animals, Type III Nrg1
+/2 n=8 paws from 5 animals). There was
no statistically significant difference between the genotypes.
doi:10.1371/journal.pone.0025108.g003
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neuron survival, the reduced levels of Type III Nrg1 expressed in
the heterozygote are sufficient to support sensory neuron survival
into and throughout adulthood.
Sensory neuron cutaneous projections are not affected in
Type III Nrg1
+/2 mice
Although we did not find any loss of sensory neuron soma in the
Type III Nrg1+/2 mice, it was possible that these animals had a
deficit in sensory cutaneous projections. To address this possibility,
we quantified TrkA, Ret and TRPV1 protein in samples of
galabrous hindpaw skin from WT and Type III Nrg1+/2 mice by
immunoblot (Figure 3B,C).Wedidnotseeanyloss oftheseproteins
in the galabrous skin of Type III Nrg1
+/2 mice, indicating that
cutaneous projections in these animals were grossly normal.
Type III Nrg1
+/2 animals have a reduction in functional
TRPV1 along sensory neuron axons
The capsaicin receptor, TRPV1, is a cation-permeable ion
channel found in nociceptive sensory neurons that contributes
to noxious temperature sensation and thermal hypersensitivity
to pain under inflammatory conditions [3,19]. We had
previously verified that Type III Nrg1 and TRPV1 are found
in the same sensory neuron cell bodies in vivo by labeling
transverse sections through L4/L5 DRG from adult WT mice
with antibodies against TRPV1 and Type III Nrg1
(Figure 1A(g–i)).
TRPV1 located along axons and at peripheral terminals is
most physiologically relevant to temperature and pain sensa-
t i o n .W ev e r i f i e dt h a tT y p eI I IN r g 1a n dT R P V 1w e r ec o -
expressed in the same sensory neuron axons by labeling sections
from the plantar hindpaw skin of adult WT mice with
antibodies against Type III Nrg1 and TRPV1 (Figure 1B (d9–
f9)). Additionally, Type III Nrg1 and TRPV1 are co-expressed
in vitro along the axons of sensory neurons from P21 WT male
mice (Figure 4D).
As TRPV1 is permeable to calcium, we measured functional
TRPV1 along sensory axons by quantifying agonist-induced
changes in intracellular calcium. For twenty seconds, 1 mM
capsaicin was focally applied to cultures of DRG sensory neurons
from P21 WT male mice. Capsaicin treatment resulted in a 16
percent increase in intracellular calcium from baseline ([(F2F0)/
Figure 4. Sensory axons, but not soma, from Type III Nrg1
+/2 mice show reduced capsaicin responsiveness compared to axons from
WT mice. (A) Representative traces of intracellular calcium along sensory axons in response to 1 mM capsaicin or 56 mM KCl. The change in
intracellular calcium from baseline over time ([(F2F0)/F0]*100) is shown for WT (left) and Type III Nrg1
+/2 (right) axons. Hatched diagonal lines
indicate where the time course was non-continuous. (B) Quantification of the maximum change in intracellular calcium in response to application of
1 mM capsaicin or 56 mM KCl by genotype. Averages of 5 animals per genotype were compared using a Student’s t-test. Type III Nrg1
+/2 axons
showed a significantly decreased response to capsaicin (p,0.05), but not to KCl, relative to WTs. Graph shows mean6SEM. (C) Type III Nrg1
+/2
sensory soma show normal response to capsaicin. Quantification of maximal change in fluorescence from baseline ([(F2F0)/F0]*100) in WT or Type III
Nrg1
+/2 sensory neuron soma in response to 1 mM capsaicin or 56 mM KCl. Average responses from 4 WT and 4 Type III Nrg1
+/2 animals to
application of capsaicin or KCl were compared by genotype using a Student’s t-test. There was no statistically significant difference between
genotypes. Graphs show mean6SEM. (D) Type III Nrg1 (green) and TRPV1 (red) are co-expressed along P21 WT cultured sensory neuron axons
identified with a pan-axonal (PA) marker (blue). White arrows indicate examples where Type III Nrg1 and TRPV1 are in close proximity. Scale bar
equals 10 mm. (E) P21 WT and Type III Nrg1
+/2 sensory neuron cultures have equivalent levels of total TRPV1 protein. Total TRPV1 protein
measurement by immunoblot. The 95 kD TRPV1 band and the 35 kD GAPDH band are shown from a representative experiment comparing protein
from P21 WT and Type III Nrg1
+/2 cultures. Quantification of fold change in intensity of TRPV1:GAPDH normalized to WT average. There was no
statistically significant change in the ratio of TRPV1 to GAPDH between genotypes (WT, Type III Nrg1
+/2, n=3 animals). Genotype comparisons were
made using a Student’s t-test. Graph shows mean6SEM.
doi:10.1371/journal.pone.0025108.g004
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with 10 mM capsazapine, a selective TRPV1 antagonist (data not
shown). In addition, no response to capsaicin was seen when
similar experiments were done using cultures of DRG sensory
neurons from TRPV1
2/2 mice (data not shown). Next, we
compared the response to capsaicin along WT axons to that seen
along sensory axons from Type III Nrg1
+/2 mice. Axons from
Type III Nrg1
+/2 mice had a significantly reduced maximum
change in fluorescence in response to focal application of 1 mM
capsaicin compared to WT axons (WT, 15.9462.61%; Type III
Nrg1
+/2,8 . 8 2 61.63%; p,0.05) (Figure 4B). Interestingly, there
was not a significant difference between the genotypes when
comparing the maximum somal response to capsaicin (Figure 4C;
WT, 72.3627.5%; Type III Nrg1
+/2,8 4 . 8 625.3%; p=0.75).
Finally, there was no effect of genotype on the maximum change
in fluorescence in response to depolarization with 56 mM KCl
either along axons (Figure 4B; WT, 3.0960.95%; Type III
Nrg1
+/2,2 . 5 0 60.56%; p=0.63) or within soma (Figure 4C,
WT, 35.8626.3%; Type III Nrg1
+/2,6 6 . 4 637.7%; p=0.23),
indicating that the decreased calcium signal in response to
capsaicin seen in Type III Nrg1
+/2 axons was not the result of
changes in voltage gated calcium or tetrodotoxin (TTX)-resistant
sodium channels. Cumulatively, these data show that the TRPV1
deficit in Type III Nrg1
+/2 sensory neurons appears to be
localized to axons, and does not appear to be indicative of
abnormalities in other axonally-localized calcium-permeable ion
channels. This deficit in functional TRPV1 along the axons of
Type III Nrg1
+/2 sensory neurons is consistent with the reduced
capsaicin-induced thermal hypersensitivity to pain seen in these
animals.
Acute activation of Type III Nrg1 back signaling enhances
levels of functional TRPV1 receptors along WT sensory
neuron axons
Type III Nrg1 is a bi-directional signaling molecule. While Type
III Nrg1 acting as a ligand can stimulate ErbB receptor tyrosine
kinase signaling, Type III Nrg1 signaling as a receptor can be
activated by interaction with ErbB receptor tyrosine kinases or by
depolarization [1,22]. As Type III Nrg1 and TRPV1 are expressed
in the same cell, we hypothesized that Type III Nrg1 was affecting
TRPV1 by signaling as a receptor. Type III Nrg1 signaling as a
receptor (Type III Nrg1 back signaling) can exert both transcrip-




independent effects of reducing levels of Type III Nrg1, we
compared total TRPV1 protein in cultures from P21 male WT and
Type III Nrg1
+/2 mice (Figure 4E). As we found no difference in
total TRPV1 protein between the genotypes, we concluded the
effect of Type III Nrg1 signaling on functional TRPV1 along axons
was most likely to be transcription-independent.
To test whether Type III Nrg1 back signaling acutely affects
levels of functional TRPV1 along sensory neuron axons, we used a
calcium imaging paradigm with multiple applications of capsaicin
where the fourth and fifth capsaicin applications were separated by
a 12 minute rest period during which Type III Nrg1 back
signaling could be acutely stimulated (Figure 5A). Repeated
applications of capsaicin cause progressively smaller responses,
most likely due to calcium dependent desensitization of TRPV1
channels [25]. When we treated WT sensory axons with 4
capsaicin applications spaced 4 minutes apart there was a
Figure 5. Stimulation of Type III Nrg1 signaling enhances response to capsaicin in WT sensory axons. (A) Representative traces of
intracellular calcium along WT sensory axons in response to repeated applications of 1 mM capsaicin followed by application of 56 mM KCl. The
maximum percent change in intracellular calcium ([(F2F0)/F0]*100) in response to capsaicin decreased between the 4
th and 5
th capsaicin applications
under control conditions (left), but increased when Type III Nrg1 signaling was stimulated by sErbB4-ECD application during that interval (right). (B)
Quantification of percent change in maximum response to capsaicin between the 4
th and the 5
th capsaicin application ([(F52F4)/F4]*100) by
treatment. WT sensory axons showed a significantly enhanced response to capsaicin when Type III Nrg1 signaling was stimulated with sErbB4-ECD
(WT CON, n=10 animals; WT B4, n=7 animals; Student’s t-test, ***p,0.001). Graph shows mean6SEM.
doi:10.1371/journal.pone.0025108.g005
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th
capsaicin application after a 12 minute rest period was on
average 19.7865.71% smaller than the response to the 4
th
capsaicin application (Figure 5B). To stimulate Type III Nrg1
back signaling, we applied a solubilized form of the extracellular
domain of the ErbB4 receptor tyrosine kinase (sErbB4-ECD).
Stimulation of Type III Nrg1 back signaling during this
12 minute interval reversed the decrease in capsaicin responsive-
ness, and in fact increased the amplitude by 24.1168.07%
(Figure 5B). This increase in capsaicin responsiveness following
stimulation of Type III Nrg1 back signaling was significantly
greater than the decrease seen under control conditions
(p,0.001). Importantly, stimulation of Type III Nrg1 back
signaling did not affect response to depolarization with KCl (data
not shown), indicating that the target of Type III Nrg1 back
signaling was TRPV1 and not voltage-gated calcium or TTX-
resistant sodium channels. Thus, acutely stimulating Type III
Nrg1 back signaling along WT sensory axons enhances functional
axonal TRPV1.
PtdIns3K mediates signaling between Type III Nrg1 and
TRPV1
Levels of functional, surface TRPV1 in sensory neuron soma or
HEK-293 cells are known to be modulated by a number of
signaling cascades including PtdIns3K [4,5,6]. Type III Nrg1 back
signaling also activates PtdIns3K in cultures from P21 WT sensory
neurons (Figure 6A, B). 15-minute stimulation of Type III Nrg1
signaling with sErbB4-ECD resulted in an increase in the ratio of
pAKT-AKT in whole cell lysates from P21 WT sensory neuron
cultures, as assayed by immunoblot (Figure 6A(a); WT B4,
4.860.9-fold increase from WT CON; p,0.05). This effect of
Type III Nrg1 signaling as a receptor is pathway specific as the
same stimulation paradigm did not change the ratio of pERK-
ERK (Figure 6A(b); p=0.98). Additionally, 15-minute stimulation
with sErbB4-ECD increased the fluorescence intensity of pAKT
staining along axons of cultured sensory neurons from P21 WTs
(Figure 6B; WT B4, 2.360.4-fold increase from WT CON;
p,0.05), consistent with Type III Nrg1 activation of PtdIns3K
signaling along sensory axons. We then investigated whether
PtdIns3K activation mediates signaling between Type III Nrg1
and TRPV1. When PtdIns3K signaling was blocked by bath
application of 50 mM LY294002 or 20 nM wortmannin during
calcium imaging, there was no effect on baseline response to
capsaicin (data not shown), but the effect of stimulating Type III
Nrg1 back signaling on capsaicin responsiveness was abolished
(6C; WT LY CON, 212.263.7% decrease between 4
th and 5
th
capsaicin applications; WT LY B4, 220.061.7%; WT WM
CON, 22.566.7%; WT WM B4, 217.469.5%).
Figure 6. PtdIns3K activation is required for Type III Nrg1-induced enhancement of capsaicin responsiveness. (A) 15-minute
stimulation of Type III Nrg1 signaling with sErbB4-ECD significantly increased the ratio of pAKT-AKT in whole cell lysates from P21 WT sensory neuron
cultures (a: CON, n=3; B4, n=4; Student’s t-test, *p,0.05). This increase was blocked by pre-incubation with 20 nM wortmannin (WM), an inhibitor of
PtdIns3K activity. (b) The same stimulation of Type III Nrg1 with sErbB4-ECD did not activate the MAPK pathway as illustrated by the lack of effect on
the ratio of pERK-ERK. (B) Stimulation of Type III Nrg1 signaling with sErbB4-ECD significantly increased average fluorescence intensity (AFI) levels for
pAKT staining along P21 WT cultured sensory axons (15 minutes; CON, n=3; B4, n=3; Student’s t-test, *p,0.05). Scale bars equal 10 mm. (C) Blocking
PtdIns3K signaling with 50 mM LY294002 or 20 nM wortmannin blocked the Type III Nrg1-induced enhancement of functional TRPV1 (LY CON, n=3
animals; LY B4, n=2; WM CON, n=10; WM B4, n=7). Comparisons between CON and all treatment groups were made using an ANOVA with a Holm-
Sidak post-hoc test for multiple comparisons. All graphs show mean6SEM.
doi:10.1371/journal.pone.0025108.g006
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the second, but not the first, application of capsaicin
along sensory axons
The enhancement of functional TRPV1 seen following acute
stimulation of Type III Nrg1 back signaling in WT sensory axons
could be due to either insertion of new TRPV1 receptors or
modifications of pre-existing receptors that alter channel func-
tionality. To distinguish between these possibilities we pre-treated
cultures with sErbB4-ECD for 12 minutes and then applied 2
pulses of capsaicin spaced 4 minutes apart, reasoning that the
channels should be in a relatively un-desensitized state when we
applied the first pulse of capsaicin, but not when we applied the
second one. If stimulation of Type III Nrg1 back signaling
increased the number of functional TRPV1 receptors on the
axonal membrane, we would expect to see an increase in response
to the first application of capsaicin in cultures pre-treated with
sErbB4-ECD. In fact, stimulating Type III Nrg1 signaling resulted
in a slight, not significant increase in response to the first capsaicin
application (Figure 7B; WT B4, 1.27-fold increase, p=0.17).
However, if stimulation of Type III Nrg1 signaling affected
receptor desensitization, we would expect to see an increase in the
response to the second application of capsaicin (when the receptors
are in a desensitized state) in cultures pre-treated with sErbB4-
ECD. Indeed, the amplitude of the response to the second
application of capsaicin was significantly greater in cultures where
Type III Nrg1 signaling as a receptor had been stimulated by pre-
incubation with sErbB4-ECD (Figure 7C; WT B4, 1.93-fold
increase, p,0.05). In both control and sErbB4-ECD treated
cultures the response to the second application of capsaicin was
smaller than the first, most likely due to calcium-dependent
tachyphalaxsis. In control cultures, there was on average a
65.6663.36% decrease in responsiveness between the first and
second capsaicin applications (Figure 7E). However, in cultures
stimulated with sErbB4-ECD this decrease was reduced to
49.6764.30%, a statistically significant difference from control
conditions (Figure 7E; p,0.05). There was no effect of pre-
stimulation with sErbB4-ECD on responsiveness to depolarization
with KCl (p=0.38; Figure 7D). Therefore, the major effect of
stimulating Type III Nrg1 back signaling would appear to be a
change in the degree of desensitization.
sErbB4-ECD stimulation does not affect functional TRPV1
by blocking signaling between endogenous Nrg1 and
ErbB receptors
It was possible that all the effects of applying sErbB4-ECD on
capsaicin responsiveness were due to blockade of endogenous
Nrg1 stimulation of ErbB3 receptors located on adjacent Schwann
cells, rather than to direct stimulation of Type III Nrg1 back
signaling. If this alternative scenario were true then endogenous
ErbB receptor-mediated signaling should be tonically depressing
levels of functional TRPV1. Thus, blocking ErbB receptor
signaling should disinihibit this inhibition and enhance levels of
functional TRPV1. To test this possibility, we decided to block
ErbB receptor-mediated signaling by applying the ErbB kinase
Figure 7. Pre-treatment with sErbB4-ECD enhances response to a second application of capsaicin along sensory axons. (A) Sensory
neuron cultures from P21 WT mice were incubated with sErbB4-ECD or control media for 12 minutes before two 1 mM pulses of capsaicin were
applied (spaced 4 minutes apart), followed by application of 56 mM KCl. Within axons that responded to both capsaicin and KCl, the percent change
in fluorescence from baseline ([(F2F0)/F0]*100) in response to both applications of capsaicin as well as KCl was calculated. Axonal responses were
averaged by animal and normalized to the WT CON average. (B–C) Quantification of the maximum response to the first (B) or second (C) applications
of 1 mM capsaicin were compared by treatment. Pre-treatment with sErbB4-ECD significantly increased the maximum response to the second pulse of
capsaicin (WT CON, n=8 animals; WT B4, n=9 animals; *p,0.05). There was a trend towards an increase in response to the first pulse of capsaicin
following sErbB4-ECD pre-treatment (p=0.17). (D) Quantification of the maximum response to KCl by treatment. sErbB4-ECD pre-treatment had no
effect on the maximum response to KCl (p=0.38). (E) The percent change between the maximum response to the first and second capsaicin
applications was calculated and axonal values were averaged by animal. Quantification of this percent change in response by treatment; Cultures pre-
treated with sErbB4-ECD showed significantly less of a decrease in responsiveness to capsaicin between the first and second capsaicin applications
(*p,0.05). All treatment comparisons were made using a Student’s t-test. Graphs show mean6SEM.
doi:10.1371/journal.pone.0025108.g007
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receptor-mediated signaling, as indicated by its ability to block
soluble Nrg1 (sNrg1)-induced stimulation of ErbB receptors and
activation of ERK (Figure 8A). We then incubated our sensory
neuron cultures in this concentration of ErbB receptor inhibitor
for 15 minutes prior to applying 2 pulses of capsaicin, reasoning
that if sErbB4-ECD was exerting its effects by blocking
endogenous ErbB receptor signaling then directly blocking ErbB
receptor signaling should mimic the effect of sErbB4-ECD
application. Instead, we found that blockade of ErbB receptor
signaling had no effect on subsequent capsaicin responsiveness
(Figure 8B & C). This result provided further evidence that acutely
stimulating Type III Nrg1 back signaling along WT sensory axons
enhances functional axonal TRPV1.
Stimulation of Type III Nrg1 back signaling with sErbB4-
ECD fails to rescue deficits in functional TRPV1 along
Type III Nrg1
+/2 sensory axons
As acute stimulation of Type III Nrg1 back signaling enhances
functional TRPV1 along sensory axons, and Type III Nrg1
+/2
sensory axons have reduced levels of TRPV1, we attempted to
rescue levels of functional TRPV1 along Type III Nrg1
+/2 axons
by acutely stimulating Type III Nrg1
+/2 sensory neuron cultures
with sErbB4-ECD. Using the capsaicin application paradigm
described above (for Figure 5), we found that Type III Nrg1
+/2
sensory axons showed the same degree of desensitization to
repeated capsaicin applications as WT axons. In Type III Nrg1
+/2
sensory axons a 5
th capsaicin application after a 12 minute rest
period was on average 17.666.4% smaller than the response to
the 4
th capsaicin application, which was not significantly different
than the 19.7865.71% decrease seen in WT axons (p=0.8;
Figure 9B). Unexpectedly, we found that acute stimulation of Type
III Nrg1 back signaling along Type III Nrg1
+/2 sensory axons
during this 12 minute interval did not enhance the response to
capsaicin as was seen in WT axons (Figure 9B; Type III Nrg1
+/2
B4, 29.666.21%; for reference, WT B4, +24.1168.07%). Thus,
sensory axons with reduced Type III Nrg1 were deficient in both
basal levels of functional TRPV1 and in the ability to acutely up-
regulate functional TRPV1 in response to exogenous stimulation
of Type III Nrg1 back signaling.
Stimulation of Type III Nrg1 back signaling with sErbB4-
ECD does not activate PtdIns3K signaling along Type III
Nrg1
+/2 sensory axons
Axons from Type III Nrg1
+/2 animals fail to up-regulate
functional TRPV1 in response to stimulation of Type III Nrg1
back signaling. We wondered if this impairment resulted from an
inability to activate PtdIns3K signaling. To test this, we stimulated
P21 WT and Type III Nrg1
+/2 cultures with sErbB4-ECD for
15 minutes and then quantified the intensity of pAKT staining
along sensory axons. When stimulated with sErbB4-ECD, cultures
from WT animals showed a significant increase in axonal pAKT
(1.9-fold increase; p,0.05), but cultures from Type III Nrg1
+/2
animals did not (p=0.97) (Figure 10B). Both P21 WT and Type
III Nrg1
+/2 sensory neurons showed a robust activation of
PtdIns3K signaling in response to a five-minute stimulation with
100 ng/ml NGF (data not shown; WT NGF, 1.860.28-fold
change from WT CON; p,0.05; Type III Nrg1
+/2 NGF,
2.2560.54-fold change from WT CON; p,0.05). Thus, the deficit
in PtdIns3K activation observed in Type III Nrg1
+/2 sensory
axons was specific to stimulation of Type III Nrg1 back signaling.
That exogenous stimulation of Type III Nrg1 back signaling along
Figure 8. Blockade of ErbB signaling does not enhance response to capsaicin in WT sensory axons. (A) Incubation of P21 WT sensory
neuron cultures with soluble Nrg1 (sNrg1) stimulates ErbB signaling and activates ERK (measured as a ratio of pERK to GAPDH). This sNrg1-induced
activation of ERK can be blocked by incubation with 1 mM PD158780, an ErbB kinase inhibitor (n=3 animals per condition; *p,0.05). (B–D) Blockade
of ErbB signaling does not enhance response to application of capsaicin or KCl. Sensory neuron cultures from P21 WT mice were incubated with 1 mM
PD158780 or control media for 12 minutes before two 1 mM pulses of capsaicin were applied (spaced 4 minutes apart), followed by application of
56 mM KCl. Within axons that responded to both capsaicin and KCl, the percent change in fluorescence from baseline ([(F2F0)/F0]*100) in response
to both applications of capsaicin as well as KCl was calculated. Axonal responses were averaged by animal and normalized to the WT CON average.
Quantification of the maximum response to the first (B) or second (C) applications of 1 mM capsaicin or KCl (D) were compared by treatment.
Blockade of ErbB signaling with 1 mM PD158780 did not affect response to the first or second application of capsaicin, or to KCl (WT CON, n=7
animals; ErbB Inh, n=7 animals).
doi:10.1371/journal.pone.0025108.g008
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+/2 sensory axons neither activated PtdIns3K, nor
enhanced functional TRPV1, is consistent with the idea that a
Type III Nrg1-activated PtdIns3K signal is required to enhance
functional TRPV1 in WT sensory axons.
The absence of sErbB4-ECD-stimulated signaling in Type III
Nrg1
+/2 sensory neuron axons was unexpected. To determine if
the heterozygous sensory neurons lacked axonal Type III Nrg1 we
examined Type III Nrg1 expression along sensory axons using
antibodies that specifically recognize Type III Nrg1 or the Nrg1-
ICD. In cultures from P21 mice, Type III Nrg1 immunofluores-
cent staining was punctate along WT and Type III Nrg1
+/2
sensory neuron axons identified with the nociceptive-specific
marker, peripherin (Figure 11). Quantification of the number of
Type III Nrg1
+ punctae per 100 mm of sensory axon demonstrat-
ed that the number of Type III Nrg1
+ punctae was reduced by fifty
percent along Type III Nrg1
+/2 axons (Figure 11B; WT, 2263
puncta/100 mm; Type III Nrg1
+/2,1 3 63 puncta/100 mm;
p,0.05). We found an even greater decrease in expression of
Nrg1 proteins containing the ICD domain along Type III Nrg1
+/2
sensory neuron axons relative to WT axons (Figure 12B; WT, 661
puncta/100 mm; Type III Nrg1
+/2,1 60.3 puncta/100 mm;
p=0.001). Therefore, although total levels of axonal Type III
Nrg1 were reduced 2-fold in the heterozygotes, there was a 6-fold
decrease in the level of signaling-competent axonal Type III Nrg1 in
the heterozygotes. The preferential decrease in axonal Nrg1-ICD is
likely to result from changes in the dynamics of proteolytic
processing and targeting to axons, rather than altered splicing of
TMc containing transcripts. In both WT and Type III Nrg1
+/2
DRG ,90% of transcripts contained the TMc domain encoding
exon, whereas less than 10% utilized the b3 splice choice that would
result in expression of just the Type III Nrg1b3 isoform (data not
shown). It is likely that the reduced level of Type III Nrg1 ICD-
containing protein along Type III Nrg1
+/2 sensory axons was
insufficient to activate PtdIns3K or regulate functional TRPV1.
Discussion
Type III Nrg1 is involved in the perception of noxious
temperatures, particularly under acute inflammatory conditions.
Type III Nrg1
+/2 mice display deficits in their response to noxious
heat, and in their ability to develop thermal hypersensitivity to
pain following capsaicin-induced inflammation of the hindpaw.
Consistent with this behavioral phenotype we show that Type III
Nrg1 is involved in the regulation of functional TRPV1 along
sensory neuron axons. Type III Nrg1
+/2 mice have reduced
functional TRPV1 along their sensory axons. Additionally, acute
stimulation of Type III Nrg1 back signaling in WT sensory axons
enhances functional TRPV1 in a manner that is dependent on
PtdIns3K activation. Acute stimulation of Type III Nrg1 back
signaling in Type III Nrg1
+/2 sensory axons, however, does not
enhance functional TRPV1 or activate PtdIns3K, consistent with
their blunted capsaicin induced thermal hypersensitivity. Togeth-
er, these data provide support for a model whereby Type III Nrg1
back signaling in nociceptive sensory neurons helps regulate
Figure 9. Acute stimulation of Type III Nrg1 signaling in Type III Nrg1
+/2 sensory axons does not rescue functional TRPV1 deficits.
(A) Representative traces of intracellular calcium along Type III Nrg1
+/2 sensory axons in response to repeated applications of 1 mM capsaicin
followed by application of 56 mM KCl. The maximum percent change in intracellular calcium ([(F2F0)/F0]*100) in response to capsaicin decreased
between the 4
th and 5
th capsaicin application in Type III Nrg1
+/2 axons under control conditions (left) and did not increase when Type III Nrg1
signaling was stimulated by sErbB4-ECD application during that interval (right). (B) Quantification of percent change in maximum response to
capsaicin between the 4
th and the 5
th capsaicin application ([(F52F4)/F4]*100) by treatment. Results from WT sensory axons are included for
comparison (WT CON, n=10; WT B4, n=7; ***p,0.001). Type III Nrg1
+/2 axons did not show a statistically significantly enhanced response to
capsaicin when Type III Nrg1 signaling was stimulated (Type III Nrg1
+/2 CON, n=6 animals; Type III Nrg1
+/2 B4, n=8). All comparisons between
genotypes and treatments were made using an ANOVA with a Holm-Sidak post-hoc test for multiple comparisons. Graph shows mean6SEM.
doi:10.1371/journal.pone.0025108.g009
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the ability to sense heat and to develop thermal hypersensitivity to
pain under inflammatory conditions.
Type III Nrg1
+/2 animals have hypomyelinated peripheral
nerves, disorganized Remak bundles and reduced conduction
velocities [26,27]. Despite these general effects on peripheral
nerves, the Type III Nrg1+/2 animals have limited impairments
in their response to noxious heat, an enhanced response to noxious
cold and normal responses to mechanical stimuli. Over-expression
of a dominant negative form of ErbB4 (DN-ErbB4) in non-
myelinating Schwann cells results in decreased response to both
noxious hot and cold stimuli that was attributed to a progressive
loss of C-fiber sensory neurons [28]. These differences between
our mice and the DN-ErbB4 mice indicate that the behavioral
phenotype in the Type III Nrg1
+/2 animals cannot be attributed
to a loss of stimulation of Schwann cell ErbB receptors. Thus
although altered Schwann cell function might contribute to the
phenotype reported here, additional aspects of Type III Nrg1
signaling are likely to account for the sensory deficits.
Type III Nrg1 heterozygotes also differ from mice in which all
Nrg1 expression is disrupted specifically in a population of small-
diameter C-fiber nociceptive sensory neurons that express the
sodium channel, Nav1.8 [29]. These Nav1.8-specific Nrg1
2/2
animals showed no changes in response to thermal or mechanical
stimuli, except for a deficit in response to tail pinch. Nav1.8 is not
expressed in a population of peptidergic, TRPV1
+ sensory neurons
that are essential for heat pain sensation [30,31]. Thus, the most
parsimonious explanation for the difference between our findings
and those of Fricker et al [29] is that Type III Nrg1 signaling in
TRPV1
+/Nav1.8
2 nociceptive sensory neurons, contributes to
heat pain sensation.
Although the present study clearly shows an effect of Type III
Nrg1 signaling on TRPV1, it is likely that Type III Nrg1 affects
additional aspects of sensory neuron function that contribute to the
sensory behavioral deficits seen. In fact, previous results from our
laboratory demonstrate that Type III Nrg1 back signaling
regulates functional surface a7* nAChRs [2,32], indicating that
Type III Nrg1 modulates multiple ion channels that contribute to
temperature and pain sensation. Type III Nrg1 is also expressed in
other neurons that contribute to response to painful stimuli and
peripheral nerves in the Type III Nrg1 heterozygotes are
hypomyelinated with altered conduction velocities [26,27]. While
we cannot rule out a contribution of hypomyelination or Type III
Nrg1 signaling in other areas of the nervous system to the
phenotype in the Type III Nrg1
+/2 mice, the modality specific
nature of the behavioral deficits in the Type III Nrg1
+/2 mouse is
consistent with a deficiency in Type III Nrg1 signaling in a specific
population of sensory neurons.
Consistent with our behavioral results, we present evidence that
Type III Nrg1 acting along sensory axons can regulate levels of
functional TRPV1. Under inflammatory conditions, rapid activa-
tion of a variety of signaling pathways can acutely increase
TRPV1 levels on the surface of sensory neurons, potentiate
TRPV1 channel function and decrease the threshold for TRPV1
channel activation [33,34]. All of these mechanisms render sensory
neurons more responsive to subsequent thermal stimulation,
notably at temperatures at which they would have previously
remained quiescent. We demonstrate that acute stimulation of
Type III Nrg1 back signaling rapidly increases functional TRPV1
along cultured WT sensory neuron axons in a PtdIns3K-
dependent manner. Previous studies linking PtdIns3K activation
by NGF-TrkA signaling to acute insertion of new TRPV1
receptors into the cell membrane [4,5,6] relied on measurements
made in either the soma of cultured mouse sensory neurons or
heterologous expression systems. It was assumed that an analogous
mechanism occurs along sensory axons and at peripheral nerve
terminals, where this signaling would matter in vivo. Our data
provide evidence that a PtdIns3K-dependent enhancement of
TRPV1 can also occur along sensory axons in vitro. Furthermore,
we show that Type III Nrg1 is present along TRPV1
+ peripheral
Figure 10. sErbB4-ECD stimulation of Type III Nrg1
+/2 sensory
neuron cultures fails to activate PtdIns3K along sensory axons.
(A) Representative images of pAKT staining along WT and Type III
Nrg1
+/2 sensory axons stimulated for 15 minutes with either control or
sErbB4-ECD media. All scale bars equal 10 mm. (B) Quantification of
pAKT average fluorescence intensity (AFI) along WT and Type III Nrg1
+/2
sensory axons under various treatment conditions. sErbB4-ECD stimula-
tion significantly increased AFI levels for pAKT staining along P21 WT
sensory axons (WT CON, n=3 animals; WT B4, n=3; *p,0.05) but not
along sensoryaxons from Type III Nrg1




treatments and genotypes were made using an ANOVA with a Fischer’s
PLSD post-hoc analysis. Graph shows mean6SEM.
doi:10.1371/journal.pone.0025108.g010
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for our mechanism to occur in a physiologically relevant context in
vivo.
Stimulating Type III Nrg1 signaling in Type III Nrg1
+/2
sensory neuron cultures had no effect on either functional axonal
TRPV1 or PtdIns3K activation. Immunofluorescent detection of
Type III Nrg1 and Nrg1-ICD protein revealed that Type III
Nrg1
+/2 animals have a two- and six-fold decrease in the number
of Type III Nrg1
+ and Nrg1-ICD
+ punctae along their sensory
axons, respectively, as compared to WTs. Therefore, it is likely
that a threshold level of signaling-competent, ICD-containing
Type III Nrg1 protein along axons is needed to achieve detectable
effects on TRPV1 and PtdIns3K. These results also demonstrate
that in vitro, there are two pools of Type III Nrg1 along
nociceptive axons: one that is competent to engage in bi-
directional signaling, the other that is not. In vivo, the latter pool
is likely to provide the axonal Type III Nrg1 required by Schwann
cells to organize axons into Remak bundles [27]. RT-PCR
analyses of Type III Nrg1 expression in mouse DRG indicates that
the majority of transcripts in both wild type and heterozygotes
encode Type III Nrg1 proteins containing the c-terminal
intracellular domain. Therefore the maintenance of the two pools
is most likely controlled by rates of proteolytic processing. We
propose that in vivo, the former, back signaling-competent pool is
preferentially found at nerve terminals where it is available for
acute regulation of receptors such as TRPV1 and a7*nAChRs
[2,32].
We hypothesize that the endogenous activator of Type III Nrg1
back signaling at peripheral nerve terminals is either ErbB
receptor expressed on keratinocytes or depolarization, as activity
has been shown to activate Type III Nrg1 back signaling both in
vitro [1] and in vivo [22]. The inability of Type III Nrg1
+/2 cultures
to acutely up-regulate levels of functional TRPV1 may explain
why Type III Nrg1
+/2 mice show profound reductions in their
ability to develop capsaicin-induced inflammatory thermal hyper-
sensitivity. Based on the strong association between the specificity
of the pain phenotype seen in Type III Nrg1
+/2 animals and the
changes seen in sensory neurons from those animals, we conclude
Figure 11. Type III Nrg1
+/2 sensory axons have reduced numbers of Type III Nrg1
+ punctae relative to WT sensory axons. (A)
Conventional microscopic images of Type III Nrg1
+ punctae (green) found along peripherin
+ axons (blue) from WT and Type III Nrg1
+/2 sensory
cultures. Scale bars equal 10 mm. (B) Quantification of the average number of punctae per 100 mm axon length from 16 WT and 15 Type III Nrg1
+/2
images. Comparison by genotype illustrates that Type III Nrg1
+/2 sensory axons have significantly fewer Type III Nrg1
+ punctae than WT sensory
axons (Mann-Whitney Rank Sum test, *p,0.05).
doi:10.1371/journal.pone.0025108.g011
Figure 12. Type III Nrg1
+/2 sensory axons have reduced numbers of Nrg1
+ punctae that contain a signaling-competent intracellular
domain (Nrg1-ICD) relative to WT sensory axons. (A) Conventional microscopic images of Nrg1-ICD
+ punctae (green) found along peripherin
+
axons (blue) from WT and Type III Nrg1
+/2 sensory cultures. Scale bars equal 10 mm. (B) Quantification of the average number of punctae per 100 mm
axon length from 14 WT and 15 Type III Nrg1
+/2 images. Comparison by genotype illustrates that Type III Nrg1
+/2 sensory axons have significantly
fewer Nrg1-ICD
+ punctae than WT sensory axons (Mann-Whitney Rank Sum test, ***p,0.001).
doi:10.1371/journal.pone.0025108.g012
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neurons is important for thermal pain sensation and the
development of thermal hypersensitivity in vivo.
Our finding that Type III Nrg1 signaling in sensory neurons
regulates functional levels of the receptor TRPV1 in a way that
may affect thermal pain sensation and inflammatory thermal
hypersensitivity also has implications for understanding the
neurobiology of sensory abnormalities occurring in schizophrenia.
Schizophrenia patients show abnormalities in pain sensitivity
[12,14,16,18,35], but these deficits were often attributed to general
cognitive deficits seen in the disease. We now provide evidence
that Type III Nrg1—a protein whose levels were decreased in
tissue from some schizophrenia patients—is important for the
perception of thermal pain, and that this behavioral effect may
result from regulation of functional axonal TRPV1 by Type III
Nrg1 signaling in nociceptive sensory neurons. This finding,
combined with prior results demonstrating regulation of axonal
a7*nAChRs by Type III Nrg1 signaling [2], contributes to a
growing body of work demonstrating that Type III Nrg1 is
important for the function of nociceptive sensory neurons. In this
way, we provide a means by which Type III Nrg1 signaling in the
periphery could contribute to deficits in pain sensing seen in
schizophrenia patients.
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